Align Technology appoints two directors to board By Investing.com
Align Technology Inc. (NASDAQ:ALGN) has appointed Paul J. Clancy and Ian Bell to its Board of Directors. Clancy, with over 30 years of experience in biotech and pharma, joins immediately, while Bell, a current Senior Vice President and COO at Alcon Inc., will join on December 10, 2026. These appointments will temporarily increase the board to 13 directors before C. Raymond Larkin, Jr. retires at the end of 2026, reducing the total to 12.
Align Technology appoints Paul Clancy and Ian Bell to board
Align Technology (ALGN) has appointed Paul Clancy and Ian Bell to its board of directors, effective November 17 and December 10, 2026, respectively. Their appointments will increase the board size from 11 to 13 directors. Both individuals will participate in the non-employee director compensation program and have entered into director indemnification agreements.
Paul J. Clancy and Ian Bell to Join Align Technology Board of Directors
Align Technology, Inc. has announced the appointment of Paul J. Clancy and Ian Bell to its Board of Directors. Paul J. Clancy, a former CFO of Alexion Pharmaceuticals and Biogen, joins immediately, bringing over 30 years of strategic, financial, and operational leadership experience. Ian Bell, Senior Vice President and Chief Operating Officer of Alcon Inc., will join on December 10, 2026, contributing broad experience across commercial, manufacturing, quality, and regulatory operations.
ALGN: Align Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Align Technology Inc. has filed an SEC Form 8-K announcing the appointment of two new directors to its board: Paul Clancy, effective immediately, and Ian Bell, effective December 10, 2026. This expands the board to 13 members temporarily, before returning to 12 upon Raymond Larkin's retirement on December 31, 2026. The appointments add significant finance, strategy, and operations experience from the healthcare sector.
Orthodontics Market to Reach USD 38.21 Billion by 2034 as Clear Aligners, Digital Workflows and Asia-Pacific Demand Reshape Care
The global orthodontics market, currently valued at USD 8.98 billion in 2025, is projected to reach USD 38.21 billion by 2034, growing at a CAGR of 17.45%. This significant expansion is driven by increasing adult and adolescent demand for aesthetic corrections, technological advancements like digital workflows, and wider distribution channels. While North America currently leads, the Asia-Pacific region is anticipated to be the fastest-growing market, with clear aligners and digital instruments fueling the market shift.
Align Technology Inc. stock underperforms Tuesday when compared to competitors
Align Technology Inc. (ALGN) shares declined 1.52% to $163.46 on Tuesday, marking its second consecutive day of losses. The underperformance occurred during a generally poor trading session for the broader stock market, with both the S&P 500 Index and Dow Jones Industrial Average also experiencing significant drops.
Should You Continue to Hold ALGN Stock in Your Portfolio?
Align Technology (ALGN) is expanding its Invisalign portfolio and increasing digital dentistry adoption through strategic alliances, contributing to a 25.4% stock gain over the past year. However, the company faces risks from currency volatility and competitive pressure from traditional and lower-priced clear aligner alternatives. Despite these challenges, analysts project an 8.4% long-term earnings growth rate for ALGN.
Dental equipment & technology stocks Q3 highlights: Dentsply Sirona
The dental equipment and technology sector reported a softer Q3, with revenues generally in line with analyst estimates but next quarter's guidance falling short. Dentsply Sirona (NASDAQ:XRAY) had the weakest performance, missing revenue and EPS estimates, while Envista Holdings (NVST) saw solid results despite a market downturn. Align Technology (ALGN) exceeded revenue expectations but offered disappointing guidance, and Henry Schein (HSIC) met expectations with strong revenue growth.
Dental equipment & technology stocks Q3 highlights: Dentsply Sirona
Dentsply Sirona (NASDAQ:XRAY) reported an underwhelming Q3 with revenues down 7.5% year on year, missing analyst expectations and full-year EPS guidance. While other dental equipment and technology companies like Envista (NYSE:NVST), Align Technology (NASDAQ:ALGN), and Henry Schein (NASDAQ:HSIC) had mixed results, Dentsply Sirona delivered the weakest performance against analyst estimates. The dental equipment and technology sector generally saw a softer Q3, with collective share prices declining and next quarter's revenue guidance falling below expectations.
An investment manager reports a 3.78M-share passive stake in Align Technology (ALGN).
Capital World Investors reported a passive beneficial ownership of 3,780,282 shares of Align Technology, Inc. (ALGN) common stock as of September 30, 2026, which represents 5.3% of the class. The investment manager holds sole voting power over 3,758,737 shares and sole dispositive power over all 3,780,282 shares. This disclosure was made in a SCHEDULE 13G SEC filing.
GrabAGun Appoints W. Bryan Hill to Board of Directors
GrabAGun Digital Holdings Inc. (NYSE: PEW) has announced the appointment of W. Bryan Hill to its Board of Directors, effective November 9, 2026. Mr. Hill, a veteran public-company executive, brings extensive experience in financial leadership, capital markets, and strategic growth, and will serve on the Audit and M&A Committees. This appointment is expected to further strengthen the Board's financial and strategic expertise as the company advances its commerce and platform strategy.
Align Technology, Inc. Stock 12‑Month Price Target Cut to $183.92, Implies 7% Upside
Analysts have cut the average 12-month price target for Align Technology, Inc. (ALGN) stock from $185.08 to $183.92, with individual forecasts ranging from $160 to $210 per share. Based on the November 11 closing price, this updated target suggests a potential upside of approximately 7%. The consensus rating from 17 covering analysts remains a "Buy," with 9 Buys, 7 Holds, and 1 Sell recommendation.
Angel Aligner Unveils Six Innovations for 2027
Angel Aligner has announced six new innovations for 2027, as detailed in a press release contributed by Business Wire. The article also lists several related news items concerning Angelalign Technology's financial results, patent disputes, and market performance in Europe and North America.
iRhythm Technologies CEO Joins Align Technology’s Board of Directors
Align Technology has appointed Quentin Blackford, President and CEO of iRhythm Technologies, to its Board of Directors, replacing the retiring Andrea Saia. Blackford brings extensive experience in global healthcare, medical technology, and digital innovation from his roles at iRhythm Technologies, Dexcom, NuVasive Inc., and Zimmer Holdings. Align Technology credits Saia for her significant contributions to the company's growth and strategic oversight during her 13-year tenure.
Paycom Software, Inc. (PAYC) Stock Forecasts
This article provides a Morningstar analyst report for Paycom Software, Inc. (PAYC), detailing that automation efficiencies continue to drive margin growth. The fair value estimate for PAYC has been raised from $170 to $200, with the current price at $237.96. Paycom is described as a cloud-based human capital management provider specializing in payroll, compliance, and HR management solutions delivered on a unified, modular platform.
Six filers amend disclosure of shares they may own in Align Technology (ALGN).
Six reporting persons, including G. Zachary Gund, Grant Gund, Alison I. Glover, Dionis Trust, Marital Trust for Gordon Gund, and Gordon & Llura Gund Foundation, have amended their beneficial ownership disclosure for Align Technology (ALGN). Collectively, they may be deemed to own 3,721,481 shares, representing 5.3% of the outstanding common stock. This amendment is based on 70,487,053 shares outstanding as of October 30, 2026.
Align Technology (ALGN) Reports Q3 Growth And Names New CEO, Is It Still Below Fair Value?
Align Technology reported strong Q3 sales and net income, along with new 2026 guidance and a new CEO, Jennifer L. Davis. The stock has seen a significant short-term gain, leading to questions about its current valuation. Analysts believe the company is still modestly undervalued, with a fair value of $188.86 against its current price of $174.26, despite some ongoing risks.
Will Earnings And Buyback Change Align Technology Stock Narrative
Align Technology reported strong Q3 2026 results, reaffirming guidance and announcing a US$270 million accelerated share repurchase. This strategic move, combined with a planned CEO transition to Jennifer L. Davis, emphasizes operational consistency and disciplined capital return. The market will now focus on how these developments reshape the investment narrative, particularly concerning international adoption, DSO partnerships, and managing pricing pressures.
Align Technology, Inc. (ALGN) stock price, news, quote and history
Align Technology, Inc. (ALGN) is a medical instruments and supplies company providing Invisalign clear aligners and iTero intraoral scanners. The article provides a detailed overview of ALGN's stock performance, key financial metrics, earnings trends, and analyst insights. It also includes company details, recent news, and comparative performance against the S&P 500.
Align Technology, Inc. (ALGN) Seasonal Returns Chart
The article provides a seasonal returns chart for Align Technology, Inc. (ALGN), showing average monthly price returns from 2016 to 2026. It includes current stock information, with ALGN closing at $166.00, up 4.16% on November 6. The content seems to be a financial data page from Yahoo Finance.
The maker of Invisalign has earned Extel recognition four times in five years.
Align Technology (Nasdaq: ALGN) has been recognized in Extel’s 2026 All-America Executive Team rankings for executive leadership, investor relations, and investor engagement. This marks the company's fourth recognition in five years, reflecting its commitment to transparent disclosure and shareholder engagement. Align's CEO, Investor Relations Program, and Investor Day all received top rankings in the Health Care Technology & Distribution sector.
Align Technology Announces $270 Million Accelerated Stock Repurchase Agreement
Align Technology, Inc. announced a new accelerated stock repurchase (ASR) agreement with Goldman Sachs & Co. LLC to repurchase $270 million of its common stock. This ASR is part of a larger $1.0 billion stock repurchase program approved in April 2025 and is expected to bring Align's total 2026 share repurchases to approximately $500 million. The transaction reflects management's confidence in the company's long-term value and will be funded with cash on hand, leaving approximately $330 million available for future repurchases.
Align expects its $270 million share buyback to bring 2026 repurchases to about $500 million.
Align Technology announced a new $270 million accelerated stock repurchase (ASR) agreement with Goldman Sachs, which is part of its existing $1.0 billion stock repurchase program. This ASR is expected to increase Align's total 2026 share repurchases to approximately $500 million. The company plans to fund this transaction with cash on hand, underscoring its confidence in long-term value and commitment to returning capital to stockholders.
Align Technology Initiates $270 Million Accelerated Share Repurchase with Goldman Sachs
Align Technology has initiated a $270 million accelerated share repurchase (ASR) agreement with Goldman Sachs & Co. LLC, following a Form 8-K filing on November 6, 2026. This ASR is part of a larger $1.0 billion stock repurchase program approved in April 2025, with $600 million remaining under that authorization. Under the agreement, Align Technology will prepay Goldman Sachs $270 million and initially receive about 1.44 million shares, with final settlement expected by approximately December 29, 2026.
Align Technology Inc. stock underperforms Thursday when compared to competitors
Align Technology Inc. (ALGN) stock fell by 3.35% on Thursday, closing at $159.37, while the broader market also experienced a downturn. The S&P 500 Index dropped 4.36% and the Dow Jones Industrial Average decreased by 3.44%. The company's stock is currently 20.49% below its 52-week high.
Align Technology names new CEO
Align Technology has appointed Jennifer L. Davis as its new president and CEO, effective December 31, 2026. Davis will succeed Joseph M. Hogan, who has served as CEO since 2015 and will retire from the board in June 2027. Davis brings 33 years of experience in innovation, digital transformation, and brand building, most recently as CEO of Procter & Gamble's global healthcare business.
Invisalign Maker Align Names P&G’s Jennifer Davis as New CEO
Align Technology, the maker of Invisalign, has appointed Jennifer Davis as its new President and CEO, effective December 31. Davis brings over 30 years of experience from Procter & Gamble, where she most recently led the global healthcare business. She succeeds Joe Hogan, who is retiring after leading Align since 2015, and is tasked with driving further growth and expanding the Invisalign brand into digital oral health.
AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS shares are soaring, what you need to know
Shares of AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS all saw significant jumps in value following election results that confirmed Democrats reclaimed majorities in the House and Senate. This outcome eased regulatory uncertainty regarding drug pricing policy, as Wall Street analysts now project a strengthening recovery for the biopharmaceutical sector. The shifting balance of power is seen as creating a more predictable regulatory climate, encouraging investments in pharmaceutical and biotechnology development.
AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS shares are soaring, what you need to know
Shares of AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS rose after election results confirmed Democrats reclaimed majorities in Congress, easing regulatory uncertainty in the biopharmaceutical sector. Wall Street analysts expect a strengthened recovery for the sector as drug pricing legislation is deemed unlikely to dominate the new legislative agenda. Broader equity markets also rebounded, viewing congressional checks and balances as a stabilizing force for policy decisions and investments.
Align Technology appoints P&G executive Jennifer Davis as CEO - Bizwomen
Align Technology Inc., the maker of Invisalign dental products, has named Jennifer Davis as its new president and CEO, effective December 31st. Davis, formerly the CEO of Procter & Gamble’s global healthcare business, will succeed Joseph Hogan, who is retiring after serving as CEO since 2015. Her appointment is expected to help extend the Invisalign brand and expand Align Technology's role in digital oral health, leveraging her experience in consumer healthcare and oral-health businesses.
Dentsply Sirona (XRAY) Q3 earnings report preview: what to look for
Dentsply Sirona (XRAY) is preparing to release its Q3 earnings report this Thursday afternoon. Analysts expect a 4.9% year-on-year revenue decline, consistent with the previous year, though the company generally beats Wall Street estimates. Peer results from Henry Schein and Align Technology offer some insight, and investor sentiment in the healthcare equipment and supplies segment has been positive, with Dentsply Sirona's stock up 14.1% in the last month.
Henry Schein Reports Q3 2026 Growth and Raises Full-Year Guidance
Henry Schein Inc. reported strong third-quarter 2026 results with $3.5 billion in sales, a 4.0% total growth, and an 8.6% increase in US dental merchandise sales. The company's GAAP net income rose by 26.2% year-over-year, and non-GAAP diluted EPS increased by 13.0%. Following these results, Henry Schein raised its full-year 2026 non-GAAP diluted EPS guidance to a range of $5.50 to $5.56, citing improved business performance and strategic growth initiatives.
Align Technology Opens 2027 Annual Research Award Program
Align Technology has launched its 2027 Annual Research Award Program, offering up to $300,000 to support university faculty research in orthodontics and dentistry worldwide. The program provides one-year awards of up to US$25,000 each across the Americas, EMEA, and APAC regions to advance patient care through scientific and technological initiatives. Align Technology has funded approximately $4.16 million in research since the program's inception in 2010.
Align Technology Opens 2027 Dental Research Award Program
Align Technology has announced the opening of its 2027 Annual Research Award Program, offering up to $300,000 in funding to support clinical and scientific dental research at universities worldwide. The program aims to advance patient care in orthodontics and dentistry, with awards available in the Americas, EMEA, and APAC regions. Applications are open to full-time and part-time university faculty, with proposals due by March 5, 2027.
Align Technology (ALGN) Names A New CEO, Is The Stock Still 18% Undervalued?
Align Technology (ALGN) recently announced a new CEO, updated guidance, and reported third-quarter earnings, leading to a recent stock rebound. Despite a 7.23% increase over the past month, the stock is down 11.05% over 90 days and 78.32% over five years. The company is considered 18% undervalued with a fair value of $188.86, contingent on successful execution of its plan to expand operating margins and address risks like soft North American Invisalign demand.
Envista earnings: what to look for from NVST
Envista Holdings (NVST) is set to announce its earnings results, with analysts expecting a 2.7% year-on-year revenue growth, a slowdown from the previous year. The company has a strong track record of beating Wall Street's expectations, and investor sentiment in the healthcare equipment and supplies segment has been positive, with Envista's stock up 5.9% over the last month.
No securities are owned by Align Technology (ALGN) CEO-elect and director Jennifer L. Davis.
Align Technology Inc. (ALGN) has reported that Jennifer L. Davis, the company's CEO-elect and director, beneficially owns no securities. According to a holding entry dated November 2, 2026, Davis holds 0 direct shares. This information was made available on EDGAR and accepted by the SEC on the same date at 05:18 PM EST.
New insider Davis Jennifer L. claimed no ownership of stock in the company (SEC Form 3)
A new SEC Form 3 filing by insider Davis Jennifer L. indicates no ownership of stock in Align Technology Inc. (ALGN). This insight was delivered by Quantisnow, a real-time market data and news platform. Quantisnow provides alerts on SEC filings, FDA decisions, analyst ratings, and insider trades to its users.
AbbVie director resigns to become CEO of Align Technology
Jennifer L. Davis has resigned from AbbVie Inc.'s Board of Directors, effective November 2, 2026. Her resignation is due to her recent appointment as Chief Executive Officer of Align Technology, Inc. The filing states that her departure is not a result of any disagreement with AbbVie's operations or policies.
Angelalign Unveils SuperElastic Clear Aligner Material for Complex Cases
Angelalign Technology Inc. has introduced SuperElastic (MC-SE), a new clear aligner material incorporating a medical-grade polyamide layer. Developed over seven years, MC-SE is designed for complex orthodontic cases, offering consistent force, increased elasticity, and improved structural strength. The company aims for the material to provide continuous force similar to nickel-titanium archwires and plans further developments as a material platform.
Align Technology Inc. stock underperforms Monday when compared to competitors despite daily gains
Align Technology Inc. (ALGN) stock advanced 2.83% on Monday, reaching $154.13, despite a mixed trading session for the broader market. While the Dow Jones Industrial Average rose, the S&P 500 Index fell. The company's stock closed 23.10% below its 52-week high.
How Investors May Respond To Align Technology (ALGN) Cautious Outlook And CEO Change
Align Technology (ALGN) recently reported Q3 2026 results and issued cautious Q4 and full-year guidance, alongside announcing a CEO transition to Jennifer L. Davis. This combination of higher year-on-year earnings, a conservative revenue outlook due to macro pressures, and new leadership from Procter & Gamble is prompting investors to scrutinize the company's execution and long-term strategy, particularly regarding margins and clear aligner penetration. Analysts anticipate mid-single-digit annual revenue expansion and higher earnings by the end of the decade, with the current valuation setup implying the market is already factoring in some uncertainty regarding the path to these projected profits.
Tempe-based Invisalign maker brings in former Proctor & Gamble exec as CEO
Align Technology Inc., the Tempe-based maker of Invisalign, has announced that Jennifer Davis will be its new CEO, effective December 31st. Davis previously served as an executive at Procter & Gamble. This appointment follows the retirement of the current CEO.
Align Technology, Inc. (AFW.F) Seasonal Returns Chart
The article provides a seasonal returns chart for Align Technology, Inc. (AFW.F), displaying the average monthly price return from 2016 to 2026. The stock closed at 133.75 EUR, up 0.75 (+0.56%) as of October 30 at 9:50:48 p.m. GMT+1.
Align Technology, Inc. Just Recorded A 9.6% EPS Beat: Here's What Analysts Are Forecasting Next
Align Technology (NASDAQ:ALGN) recently announced its third-quarter results, reporting US$1.0 billion in revenue, in line with analyst forecasts, and statutory earnings per share (EPS) of US$1.90, beating expectations by 9.6%. Despite the EPS beat, the share price saw a 3.0% decline to US$150 in the past week. Analysts have reconfirmed their future revenue and EPS forecasts for 2027, predicting US$4.26 billion in revenue and US$8.90 EPS, with no major changes to their price targets, which remain at US$187.
5 insightful analyst questions from Align Technology’s Q3 earnings call
Align Technology's Q3 2026 results showed resilient Clear Aligner demand despite a challenging environment for discretionary dental spending. The article highlights five key analyst questions from the earnings call, addressing topics such as conservative Q4 guidance, expansion into new product categories, regional market conditions, scanner demand, and the impact of China's value-based procurement policy. It also outlines catalysts for upcoming quarters, including new product adoption, stabilization of scanner revenue, and patient conversion initiatives.
Align Technology (ALGN) Stock Sees Modest Fair Value Cut As Analyst Views Split
Align Technology (ALGN) has seen its modeled fair value reduced from US$199.21 to US$188.86, reflecting a more conservative outlook from analysts. While some firms like Mizuho and Leerink maintain positive ratings, others such as Evercore ISI and Baird have adopted more neutral stances due to concerns over demand trends and valuation. This shift in perspective is driven by factors like weakening consumer backdrops and softer Invisalign demand.
Align Technology Inc. stock outperforms competitors despite losses on the day
Align Technology Inc. (ALGN) shares declined by 2.49% to $149.89 on Friday, despite an overall dismal trading session for the stock market. The S&P 500 Index fell 1.82%, and the Dow Jones Industrial Average dropped 1.09%. This fall for Align Technology Inc. ended a two-day winning streak.
5 insightful analyst questions from Align Technology’s Q3 earnings call
Align Technology reported Q3 2026 results that surpassed analyst estimates for revenue, EPS, and operating income, driven by strong Clear Aligner demand despite a challenging discretionary spending environment. Management highlighted record doctor participation and increased shipments, alongside international growth. The article focuses on five key analyst questions from the earnings call, addressing topics such as cautious Q4 guidance, new product expansion, macro impacts on different regions, scanner demand shifts, and the influence of China’s VBP policy.
Align Technology Inc (ALGN) Q3 2026 Earnings Call Highlights: Record Doctor Submitters and ...
Align Technology Inc (ALGN) reported Q3 2026 results with worldwide revenue up 1.9% year-over-year, clear aligner shipments increasing by 6.6%, and a record 91,000 doctor submitters. Despite strong international growth and exceeding non-GAAP operating margin outlook, the company faced challenges including slowed revenue growth in Systems & Services, declining clear aligner ASP, and a pressured North America GP retail market. Align provided Q4 and fiscal 2026 guidance, expecting continued strong volume but anticipating a slight decline in Clear Aligner ASP.